CA2605745A1 - Cancer specific pcna isoform binding antibodies and uses thereof - Google Patents

Cancer specific pcna isoform binding antibodies and uses thereof Download PDF

Info

Publication number
CA2605745A1
CA2605745A1 CA002605745A CA2605745A CA2605745A1 CA 2605745 A1 CA2605745 A1 CA 2605745A1 CA 002605745 A CA002605745 A CA 002605745A CA 2605745 A CA2605745 A CA 2605745A CA 2605745 A1 CA2605745 A1 CA 2605745A1
Authority
CA
Canada
Prior art keywords
cspcna
antibody
isoform
seq
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002605745A
Other languages
English (en)
French (fr)
Inventor
Robert J. Hickey
Linda H. Malkas
Lauren Schnaper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CS-KEYS Inc
Indiana University Research and Technology Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2605745A1 publication Critical patent/CA2605745A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002605745A 2005-04-27 2006-04-27 Cancer specific pcna isoform binding antibodies and uses thereof Abandoned CA2605745A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US67527505P 2005-04-27 2005-04-27
US60/675,275 2005-04-27
US68961405P 2005-06-09 2005-06-09
US60/689,614 2005-06-09
PCT/US2006/016096 WO2006116631A2 (en) 2005-04-27 2006-04-27 Cancer specific pcna isoform binding antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA2605745A1 true CA2605745A1 (en) 2006-11-02

Family

ID=37215524

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002605745A Abandoned CA2605745A1 (en) 2005-04-27 2006-04-27 Cancer specific pcna isoform binding antibodies and uses thereof

Country Status (8)

Country Link
US (4) US20080206140A1 (enExample)
EP (1) EP1874823B1 (enExample)
JP (1) JP2008539271A (enExample)
AU (1) AU2006239318A1 (enExample)
CA (1) CA2605745A1 (enExample)
EA (1) EA200702361A1 (enExample)
MX (1) MX2007013584A (enExample)
WO (1) WO2006116631A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294471B2 (en) * 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
EA200801847A1 (ru) * 2006-02-17 2009-02-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн ПЕПТИДНОЕ ИНГИБИРОВАНИЕ ВЗАИМОДЕЙСТВИЯ caPCNA ПРИ РАКЕ
CA3023068C (en) 2008-07-24 2022-06-21 Indiana University Research And Technology Corporation Cancer peptide therapeutics
WO2011044374A1 (en) * 2009-10-07 2011-04-14 Indiana University Research And Technology Corporation Capcna peptide therapeutics for cancer
US8455200B2 (en) 2009-10-15 2013-06-04 Traxxsson, Llc Measurement of PKA for cancer detection
WO2012173677A2 (en) * 2011-03-23 2012-12-20 Indiana University Research And Technology Corporation Anticancer therapeutic agents
PL3122766T3 (pl) 2014-03-24 2021-09-13 IMMCO Diagnostics, Inc. Ulepszone wykrywanie i diagnostyka przeciwciał przeciwjądrowych dla układowych i nieukładowych zaburzeń autoimmunologicznych
US10420840B2 (en) 2015-04-10 2019-09-24 Rll, Llc Anticancer therapeutic agents
CA3047230A1 (en) * 2016-12-15 2018-06-21 The National Institute for Biotechnology in the Negev Ltd. Anti-pcna monoclonal antibodies and use thereof
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2305625A1 (en) * 1997-09-29 1999-04-08 University Of Maryland, Baltimore Altered dna synthesome components as biomarkers for malignancy
US7294471B2 (en) * 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
DE602004015064D1 (de) * 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
US8574848B2 (en) * 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods

Also Published As

Publication number Publication date
EP1874823A2 (en) 2008-01-09
WO2006116631A3 (en) 2007-03-22
US20180362626A1 (en) 2018-12-20
BRPI0607676A2 (pt) 2009-09-22
US20120244076A1 (en) 2012-09-27
WO2006116631A2 (en) 2006-11-02
US20150259407A1 (en) 2015-09-17
EA200702361A1 (ru) 2008-04-28
US20080206140A1 (en) 2008-08-28
US9006396B2 (en) 2015-04-14
JP2008539271A (ja) 2008-11-13
MX2007013584A (es) 2008-04-22
EP1874823B1 (en) 2016-01-13
HK1110338A1 (zh) 2008-07-11
AU2006239318A1 (en) 2006-11-02
AU2006239318A8 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
US9006396B2 (en) CsPCNA isoform antibodies and uses thereof
EP2900265B1 (en) Anti-uroplakin ii antibodies systems and methods
US9708395B2 (en) Anti-p40 antibodies systems and methods
CN102264765B (zh) 抗muc1抗体
US20140248283A1 (en) Monoclonal antibodies against her2 antigens, and uses therefor
AU2009339802A1 (en) RBM3 as a marker for malignant melanoma prognosis
CN102803968B (zh) 食道癌标志物
JP6977105B2 (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
CN103429617B (zh) 包含抗-ck8/18复合物自身抗体的标记物及其诊断癌症的用途
WO2019045086A1 (ja) 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途
RU2706959C2 (ru) Антитело к igf-1r и его применение для диагностики рака
US20220048980A1 (en) csPCNA Isoform Antibodies And Uses Thereof
US20080241066A1 (en) Anti-PRL-3 antibodies and methods of use thereof
EP2776465A1 (en) Monoclonal antibodies against serotransferrin antigens, and uses therefor
KR101415927B1 (ko) 항―ｔｍａｐ／ｃｋａｐ２ 항체를 포함하는 암의 예후 진단용 조성물
JP6793514B2 (ja) 新規甲状腺癌関連抗原に結合する抗体および甲状腺癌診断剤
AU2013228069A1 (en) Cancer specific PCNA isoform binding antibodies and uses thereof
HK1110338B (en) Cancer specific pcna isoform binding antibodies and uses thereof
CN101208356A (zh) 癌症特异性pcna同种型结合性抗体及其用途
BRPI0607676B1 (pt) Anticorpos contra isoformas de cspcna e usos destes
JP2004024195A (ja) ヒトｓｎｋ蛋白質に対するモノクローナル抗体及び甲状腺癌判別方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131227